Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18806637 | 0.85 | ALDH1A1 (0.40) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL17802864 | 0.83 | KDM4E (0.38) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL13369214 | 0.83 | KMT2A (0.38) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL25768390 | 0.78 | ALOX15 (0.42) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL1196453 | 0.75 | CA1 (0.45) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL11248916 | 0.75 | CA1 (0.45) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL10632677 | 0.74 | KDM4E (0.37) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL13003098 | 0.74 | KDM4E (0.37) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL10632680 | 0.74 | KDM4E (0.37) | KDM4EMAPTMEN1ALDH1A1GAA | |
| SCHEMBL10632683 | 0.74 | KDM4E (0.37) | KDM4EMAPTMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407341-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407341-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | KDM4E 1083/4885MAPT 1447/4885MEN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.